ALL heads into its July 29 earnings report with the stock up 14% in a month, analysts lifting targets across the board, and options traders showing the most defensive positioning of the past year.
The options signal is the sharpest data point this week. The put/call ratio jumped to 1.41 on Tuesday — the highest reading of the past 52 weeks and more than two standard deviations above its 20-day average of 1.17. That's not a mild hedge; it's a meaningful tilt toward downside protection at a moment when the stock is near its highs. The move follows a week in which ALL gained 5.7% to close at $251.46, pulling ahead of close peers: PGR rose 6.6% on the week, CB gained 4.7%, and TRV added 3.6% — so ALL's outperformance is real, but the insurance sector broadly ran hot.
Short positioning tells a quieter story. SI sits at 3.2% of free float — modest by any measure — and has drifted lower through the month, down roughly 4% versus 30 days ago. Borrow conditions are equally relaxed: cost to borrow is running near 0.48%, barely changed on the week and well within the low-cost range. Availability is deep at around 1,496% of short interest, meaning shares to borrow are abundant. There is no squeeze dynamic here, and the low short score of 40 — ranking in the 29th percentile — confirms that bears have not been building a serious case against the stock.
The Street moved decisively to raise targets this week, though the ratings picture is mixed. Raymond James lifted its target from $260 to $300, the most bullish print on the board. Morgan Stanley moved from $215 to $240 while staying at Equal-Weight, and Keefe Bruyette raised to $255 maintaining Market Perform. The contrast is Barclays, which raised its Underweight target from $203 to $213 — higher, but still calling the stock overvalued at current levels. HSBC went a step further, upgrading its target to $264 but simultaneously downgrading to Hold. The aggregate consensus remains Hold, with 9 buys against 12 holds and a mean target near $246 — now slightly below the current price of $251. That target gap is narrow enough to read as the Street broadly agreeing the stock has run to fair value.
On the fundamental debate, bulls point to a personal auto business gaining traction — policies-in-force grew 2.8% monthly — and a recent earnings beat driven by favorable loss reserve releases. The valuation is not demanding: the P/E has re-rated higher over 30 days as earnings estimates moved up, landing around 8.6x, while EV/EBITDA is near 7.1x. The price-to-book of 1.79x has risen 0.22 points over the past month, reflecting the market's improving view of Allstate's underwriting quality. Bears flag the 89.4% combined ratio as worse than the stated long-run target of 95%, and warn that competitive pressure in personal lines could erode the pricing gains that have driven the recovery. Factor scores add nuance: earnings surprise ranks in the 84th percentile — the company has a consistent habit of beating estimates — but 12-month forward EPS growth ranks only in the 19th percentile, suggesting the market is not pricing in much incremental earnings acceleration.
Earnings history offers limited conviction either way. The May 22 print produced a small 0.8% one-day dip followed by a 3.9% five-day decline. The April 30 result moved the stock up 2% on the day but settled to only a 0.6% gain over the following week. The pattern is muted — no dramatic gap history — which makes the current PCR spike more interesting as a relative signal rather than a predictor of outcome.
With the July 29 earnings date now three weeks out, the key tension to watch is whether that PCR elevation persists or fades as the report approaches — and whether the Street's target convergence around current prices holds or prompts further upgrades if the underwriting trend continues to improve.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
